ES2185338T3 - Derivados de fumagilol y procedimientos para su fabricacion. - Google Patents

Derivados de fumagilol y procedimientos para su fabricacion.

Info

Publication number
ES2185338T3
ES2185338T3 ES99919688T ES99919688T ES2185338T3 ES 2185338 T3 ES2185338 T3 ES 2185338T3 ES 99919688 T ES99919688 T ES 99919688T ES 99919688 T ES99919688 T ES 99919688T ES 2185338 T3 ES2185338 T3 ES 2185338T3
Authority
ES
Spain
Prior art keywords
substituted
fumagilol
halogen
unsubstituted
procedures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99919688T
Other languages
English (en)
Inventor
Chung Il Hong
Jung Woo Kim
Sang Joon Lee
Soon Kil Ahn
Nam Song Choi
Ryung Kee Hong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chong Kun Dang Corp
Original Assignee
Chong Kun Dang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Corp filed Critical Chong Kun Dang Corp
Application granted granted Critical
Publication of ES2185338T3 publication Critical patent/ES2185338T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/08—Compounds containing oxirane rings with hydrocarbon radicals, substituted by halogen atoms, nitro radicals or nitroso radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Derivado de fumagilol representado por la Fórmula Química 1 o una sal del mismo farmacéuticamente aceptable: en la que, X representa un grupo hidroxi e Y representa un halógeno, o X e Y pueden formar un anillo oxiránico; B representa oxígeno o hidrógeno; y R1, R2, R3, R4 y R5 independientemente representan hidrógeno, hidroxi, acetoxi, amino substituido o no substituido, alquilo substituido o no substituido, aminoalcoxi substituido o no substituido, C1-C6 alcoxi, halógeno, ciano, trifuorometilo, nitro, alquilendioxi, formilo, acetamido o metilenoxicarboxilo, con la condición de que R1, R2, R3, R4 y R5 no representen hidrógeno al mismo tiempo.
ES99919688T 1998-05-15 1999-05-11 Derivados de fumagilol y procedimientos para su fabricacion. Expired - Lifetime ES2185338T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR19980017636 1998-05-15

Publications (1)

Publication Number Publication Date
ES2185338T3 true ES2185338T3 (es) 2003-04-16

Family

ID=19537397

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99919688T Expired - Lifetime ES2185338T3 (es) 1998-05-15 1999-05-11 Derivados de fumagilol y procedimientos para su fabricacion.

Country Status (10)

Country Link
US (1) US6063812A (es)
EP (1) EP1077964B1 (es)
JP (1) JP3370985B2 (es)
KR (1) KR100357542B1 (es)
CN (1) CN100352810C (es)
AU (1) AU3734699A (es)
CA (1) CA2331873C (es)
DE (1) DE69903279T2 (es)
ES (1) ES2185338T3 (es)
WO (1) WO1999059986A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
EP1330447A2 (en) 2000-11-01 2003-07-30 Praecis Pharmaceuticals Incorporated Peptides as met-ap2 inhibitors
US7105482B2 (en) 2000-11-01 2006-09-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
KR100455900B1 (ko) * 2001-09-27 2004-11-12 주식회사 아이디알 새로운 푸마질롤 유도체 및 그의 제조방법
KR100451485B1 (ko) 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
KR100552043B1 (ko) * 2004-02-28 2006-02-20 주식회사종근당 푸마질롤 유도체를 포함하는 비만치료용 조성물
EP1841761A4 (en) * 2005-01-26 2008-10-29 Chong Kun Dang Pharm Corp Fumagillol derivatives or processes for the preparation of fumagillol derivatives, and pharmaceutical compositions containing them
EP1967175A1 (en) * 2007-03-06 2008-09-10 Cognis IP Management GmbH Use of derivatives of sinapinic acid and compositions comprising such derivatives
US8399512B2 (en) * 2007-11-28 2013-03-19 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
CA2731020A1 (en) * 2008-07-18 2010-01-21 Zafgen, Inc. Use of antiangiogenic fumagillins in the treatment of obesity
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
WO2011044506A2 (en) 2009-10-09 2011-04-14 Zafgen Corporation Sulphone compounds and methods of making and using same
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
AU2011204267B2 (en) 2010-01-08 2015-12-03 Zafgen Corporation Fumagillol type compounds and methods of making and using same
US20130023513A1 (en) 2010-01-12 2013-01-24 Hughes Thomas E Methods and Compositions for Treating Cardiovascular Disorders
US20130266578A1 (en) 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
ES2853204T3 (es) 2010-05-25 2021-09-15 Syndevrx Inc Inhibidores de MetAP2 conjugado con polímero, y métodos terapéuticos de uso de los mismos
WO2012012642A1 (en) 2010-07-22 2012-01-26 Zafgen Corporation Tricyclic compounds and methds of making and using same
PH12013500934A1 (en) * 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
WO2012064928A1 (en) 2010-11-10 2012-05-18 Zafgen Corporation Methods and compositions for treating thyroid hormone related disorders
EP2646016B1 (en) 2010-11-29 2017-05-17 Zafgen, Inc. Treatment if obesity using non-daily administration of 6-0-(4-dimethylaminoethoxy)cinnamoyl fumagillol
WO2012074968A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors
US9189078B2 (en) 2010-12-20 2015-11-17 Apple Inc. Enhancing keycap legend visibility with optical components
KR20140006888A (ko) 2011-01-26 2014-01-16 자프겐 인크. 테트라졸화합물, 그리고, 이를 제조하는 방법 및 이를 이용하는 방법
JP5876513B2 (ja) 2011-03-08 2016-03-02 ザフゲン，インコーポレイテッド オキサスピロ［２．５］オクタン誘導体および類似体
KR101979039B1 (ko) 2011-05-06 2019-05-15 자프겐 인크. 부분 포화된 삼환식 화합물 및 그리고 그의 제조방법 및 그를 이용하는 방법
CN103748094B (zh) 2011-05-06 2016-06-29 扎夫根股份有限公司 三环磺酰胺化合物及其制备和使用方法
US9242997B2 (en) 2011-05-06 2016-01-26 Zafgen, Inc. Tricyclic pyrazole sulphonamide compunds and methods of making and using same
US9359369B2 (en) 2012-01-18 2016-06-07 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
AU2013209719A1 (en) 2012-01-18 2014-08-07 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
US9260419B2 (en) 2012-05-07 2016-02-16 Zafgen, Inc. Polymorphic salt of a metap-2 inhibitor and methods of making and using same
CA2872876A1 (en) 2012-05-08 2013-11-14 Zafgen, Inc. Treating hypothalamic obesity with metap2 inhibitors
EP2850079B1 (en) 2012-05-09 2018-05-02 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
EA028367B1 (ru) 2012-11-05 2017-11-30 Зафджен, Инк. Способы лечения заболеваний печени
AU2013337288A1 (en) 2012-11-05 2015-05-21 Zafgen, Inc. Tricyclic compounds for use in the treatment and/or control of obesity
CA2890342A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds and methods of making and using same
CN105228610A (zh) 2013-03-14 2016-01-06 扎夫根股份有限公司 治疗肾疾病和其它病症的方法
AU2014250983B2 (en) 2013-04-10 2019-04-11 Syndevrx, Inc. MetAP2 inhibitors and methods of treating obesity
TW201636342A (zh) * 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
US9969722B2 (en) 2015-12-10 2018-05-15 Syndevrx, Inc. Fumagillol derivatives and polymorphs thereof
EP3402529A1 (en) 2016-01-11 2018-11-21 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
CA3117666A1 (en) 2018-10-26 2020-04-30 Syndevrx, Inc. Biomarkers of metap2 inhibitors and applications thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH26256A (en) * 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
EP0357061B1 (en) * 1988-09-01 1994-06-08 Takeda Chemical Industries, Ltd. Angiogenesis inhibitory agent
DE69004598T2 (de) * 1989-03-06 1994-03-24 Takeda Chemical Industries Ltd 6-Amino-6-desoxyfumagillole, ihre Herstellung und ihre Verwendung.
US5290807A (en) * 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
EP0415294A3 (en) * 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
EP0555693B1 (en) * 1992-01-30 2001-09-05 Takeda Chemical Industries, Ltd. Method of producing highly watersoluble cyclodextrin complex
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative

Also Published As

Publication number Publication date
DE69903279T2 (de) 2003-08-07
EP1077964A1 (en) 2001-02-28
CA2331873C (en) 2005-12-06
CN100352810C (zh) 2007-12-05
KR19990088113A (ko) 1999-12-27
AU3734699A (en) 1999-12-06
WO1999059986A1 (en) 1999-11-25
DE69903279D1 (de) 2002-11-07
JP3370985B2 (ja) 2003-01-27
KR100357542B1 (ko) 2002-10-18
CN1301260A (zh) 2001-06-27
US6063812A (en) 2000-05-16
EP1077964B1 (en) 2002-10-02
CA2331873A1 (en) 1999-11-25
JP2002515497A (ja) 2002-05-28

Similar Documents

Publication Publication Date Title
ES2185338T3 (es) Derivados de fumagilol y procedimientos para su fabricacion.
NL350075I2 (es)
MX9302214A (es) Derivados de taxol y proceso para su preparacion
ES2188194T3 (es) 1,8-naftiridin-4(1h)-onas sustituidas como inhibidores de la fosfodiesterasa 4.
CU23006A3 (es) Nuevos ésteres derivados de compuestos fenil-ciclonuevos ésteres derivados de compuestos fenil-ciclohexil sustituidos hexil sustituidos
ATE283253T1 (de) Substituierte aminopropoxyarylderivate als lxr agonisten
ES2189502T3 (es) Metodo para la prevencion de citalopram.
CO5150159A1 (es) Derivados de 4-arilquinolin-2-ona 3-substituida como moduladores de los canales de potasio
DE69705829D1 (de) Meta-substituierte phenylsulphonamidderivate
DK0931788T3 (da) Metalloproteasehæmmere
PT923554E (pt) N-benzilpiperidina e derivados tetrahidropiridina
ECSP082712A (es) Procedimiento i para preparar derivados de tiazolidindiona
UY26048A1 (es) Derivados de piridopiranoacepinas, su preparacion y su aplicacion terapeutica
AR002711A1 (es) Un compuesto de 2-carboxindol-3-substituido,un proceso para su preparacion, un nuevo compuesto intermediario para dicho proceso, el uso del compuesto parala fabricacion de un agente terapeutico y una composicion farmaceutica que comprende dicho compuesto.
ES2191963T3 (es) Derivados triciclicos de triazolobenzazepina, proceso para la obtencion de los mismos y agentes antialergicos.
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
ES2191341T3 (es) Derivados de la 2-fenoxianilina.
MX9306529A (es) Derivados de pirazol condensado, metodo para fabricarlos y composicion farmaceutica que los contiene
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
CY1105292T1 (el) Η ενωση coniosetin (κονιοσετινη) και παραγωγα της, διαδικασια παραγωγης και εφαρμογη αυτων
AR007291A1 (es) Nuevos derivados de 10,11-dihidro-10-oxo-5h-dibenz/b, f/azepina-5-carboxamida, metodo de preparacion y su uso en la preparacion de una composicion farmaceutica
EA200000532A2 (ru) НОВЫЕ СОЕДИНЕНИЯ 7-ОКСО-2,3,7,14-ТЕТРАГИДРО-1H-БЕНЗО[b]-ПИРАНО [3,2-h]АКРИДИНКАРБОКСИЛАТА, СПОСОБ ИХ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
CO5040081A1 (es) Nuevos compuestos vidad farmaaceutica
HRP980496B1 (en) New thilozine hydroxy derivatives and a process for the preparation thereof
EA200001212A1 (ru) Усовершенствованный способ получения производных норбензоморфана с ценными фармацевтическими свойствами